share_log

Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript Summary

Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript Summary

Evogene Ltd. (EVGN) 2024年第三季度業績會議 轉錄摘要
moomoo AI ·  11/21 13:56  · 電話會議

The following is a summary of the Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript:

以下是Evogene Ltd. (EVGN) 2024年第三季度業績會議記錄摘要:

Financial Performance:

財務表現:

  • Evogene reported Q3 2024 revenues of approximately $1.8 million, a decrease from Q3 2023's $3.8 million, primarily due to a decrease in licensing revenue from Lavie Bio.

  • The company recorded an operating loss of approximately $17.6 million in the first nine months of 2024, slightly improved from $18.9 million in the same period of 2023.

  • Financing expenses for the first nine months of 2024 were approximately $0.38 million, a shift from a financing income of $2.3 million in the first nine months of 2023.

  • Projected cash usage for 2024 is approximately $8 million to $10 million, a decrease from $12.5 million in 2023, following a reduction in workforce by 16% and other expense management strategies.

  • Evogene報告2024年第三季度約180萬美元的營業收入,較2023年第三季度的380萬美元下降,主要是由於Lavie Bio的許可收入減少。

  • 公司在2024年前九個月錄得約1760萬美元的營業虧損,略有改善,較2023年同期的1890萬美元有所降低。

  • 2024年前九個月的融資費用約爲38萬美元,相比於2023年前九個月的230萬美元的融資收入有所變動。

  • 2024年的預計現金使用額約爲800萬至1000萬美元,較2023年的1250萬美元有所下降,此前通過削減16%的員工和其他費用管理策略實現。

Business Progress:

業務進展:

  • Evogene highlighted significant progress in seed production infrastructure notably in Kenya and Brazil for its subsidiary Casterra, which will support existing and future seed demands.

  • Lavie Bio announced the expansion of its bio-inoculant product, Yalos, to winter wheat and soybeans, and advancement of its bio-fungicide LAV321.

  • The company announced a collaboration with Google Cloud to develop a generative AI model for novel small molecule design, leveraging Evogene's AI tech engines.

  • Evogene在肯尼亞和巴西的子公司Casterra顯著加強了種子生產製造業務,將支持現有和未來的種子需求。

  • Lavie Bio宣佈將其生物接種劑產品Yalos擴展到冬小麥和大豆,並推進其生物殺菌劑LAV321的研發。

  • 該公司宣佈與Google Cloud合作,開發一個用於新型小分子設計的生成式人工智能模型,利用Evogene的人工智能技術引擎。

Opportunities:

機會:

  • Continued revenue growth anticipated for 2024, driven by existing seed orders from Casterra and new product launches from Lavie Bio.

  • Expansion into bioinformatics through collaboration with Google Cloud, positioning its AI tech engines at the forefront of novel molecule design.

  • 預計2024年營業收入將繼續增長,主要受Casterra的現有種子訂單和Lavie Bio的新產品推出的推動。

  • 通過與Google Cloud合作,擴展至生物信息學領域,將其人工智能技術引擎定位於新型分子設計的最前沿。

Risks:

風險:

  • Fluctuations in operating expenses and increased financial expenses related to warrants issued during fundraising could impact financial stability.

  • 營業費用波動和與籌集資金期間發行的認股權證相關的增加的財務費用可能會影響財務穩定性。

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由人工智能生成。內容準確性無法完全保證。如需更全面詳情,請參閱IR網站。本文僅供投資者參考,不具有任何指導或推薦建議。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論